I-Penam 500 IV Injection: Each vial contains Meropenem 500 mg (As Meropenem for Injection USP).
I-Penam 1 gm IV Injection: Each vial contains Meropenem 1 gm (As Meropenem for Injection USP).
- Pneumonia and Nosocomial Pneumonia
- Urinary Tract Infections
- Intra-abdominal Infections
- Gynaecological Infections, such as endometritis and pelvic inflammatory disease
- Skin and Skin Structure Infections
Empiric treatment, for presumed infections in adult patients with febrile neutropenia, used as monotherapy or in combination with anti-viral or anti-fungal agents.
Adults: The adult dose is 500 mg to 1 gm by intravenous infusion over 15-30 minutes or as intravenous bolus (5 to 20 mL) over 3-5 minutes every 8 hours.
Pneumonia, urinary tract infections, gynaecological infections such as endometritis, skin and skin structure infections: 500 mg IV every 8 hours.
Nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients and septicaemia: 1g IV every 8 hours.
Intra-abdominal infections: 500 mg to 1 gm every 8 hours.
Meningitis: 2 gm IV every 8 hours.
Renal impairment: No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min. CrCl 26-50 mL/min, 1 gm every 12 hours; CrCl 10-25 mL/min, 500 mg every 12 hours; and CrCl <10 mL/min, 500 mg every 24 hours.
Hepatic impairment: No dosage adjustments are necessary with impairment of liver function.
Hemodialysis patients should receive meropenem after dialysis has been completed.
Children: Children 3 months to 12 years: 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogen(s) and the condition of the patient.
Intra-abdominal infections: 20 mg/kg every 8 hours.
Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours.
Meningitis: 40 mg/kg IV every 8 hours.
Children over 50 kg weight: use adult dosage.
There is no experience in children with hepatic or renal impairment.
Elderly: No dosage adjustments are necessary in elderly patients unless creatinine clearance is <51 mL/min.
Rarely systemic allergic reactions (hypersensitivity), which may include angioedema and manifestations of anaphylaxis.
Lactation: Meropenem is detectable at very low concentrations in animal breast milk. Meropenem should not be used in breast-feeding women unless the potential benefit justifies the potential risk to the baby.
I-Penam 1 gm IV Injection: Each pack contains 1 vial of Meropenem 1 g, 2 ampoules of 10 ml of Water for Injection BP, one 20 ml disposable syringe and a butterfly needle.
For IV injection
I-Penam 500 mg should be reconstituted with 10 ml sterile water for injection. The reconstituted solutions are clear or pale yellow. It should be administered intravenously over 3-5 minutes.
I-Penam 1 gm should be reconstituted with 20 ml sterile water for injection. The reconstituted solutions are clear or pale yellow. It should be administered intravenously over 3-5 minutes.
For IV infusion
For intravenous infusion I-Penam may be reconstituted within the vial and then the resulting solution should be added to an I.V. container and further diluted to 50-200 ml with a compatible infusion fluid, as needed. It should be administered over 15-30 minutes.
Compatible infusion fluid
Meropenem IV is compatible with the following infusion fluids:
0.9% sodium chloride intravenous infusion
5% or 10% glucose intravenous infusion
5% glucose intravenous infusion with 0.02% sodium bicarbonate
5% glucose and 0.9% sodium chloride intravenous infusion
5% glucose with 0.225% sodium chloride intravenous infusion
5% glucose with 0.15% potassium chloride intravenous infusion
2.5% and 10% mannitol intravenous infusion
normosol-M in 5% glucose intravenous infusion.